Strata Critical Medical, Inc. - Class A Common Stock (SRTA)
Healthcare › Services-Health Services
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 14% below Graham Number — thin margin of safety
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 18.3% — good return on equity
- Revenue declining 21% annually
Strata Critical Medical, Inc. - Class A Common Stock (SRTA) is a Healthcare company operating in Services-Health Services, listed on the NASDAQ , with a market capitalisation of $501 million . Key value metrics: P/E ratio 9.6, P/B ratio 1.75, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Strata Critical Medical, Inc. - Class A Common Stock — Fundamental Analysis Summary
Strata Critical Medical, Inc. - Class A Common Stock (SRTA) is trading 14% below its Graham Number of $6.70, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 9.6x.
On financial health, SRTA shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and solid return on equity of 18.3% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.17.
StockPik's composite Value Score for SRTA is 82/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SRTA reports a thin gross margin of 17.0% (sector average: 39.4%) and a negative operating margin of -8.7%.
SRTA shows revenue declining at 21% year-over-year, with earnings growing at 251%.